Angiotensin Ii
Angiotensin Ii - Related Videos
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
0 Views •
Cited by 14 •
2016
Here we present a protocol to describe the localization of angiotensin II Type 1 receptors in the rat brain by quantitative, densitometric, in vitro receptor autoradiography using an iodine-125 labeled analog of angiotensin II.
07:21
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
0 Views •
Cited by 84 •
2015
Subcutaneous implantation of osmotic pumps provides a convenient approach for prolonged and consistent delivery of compounds. This approach has been used extensively to study both abdominal and thoracic aortic aneurysms in mice.
03:09
Sympathetic Denervation of Renal Arteries in an Angiotensin II-Induced Hypertension Mouse Model
0 Views •
2025
This video demonstrates a procedure for renal artery sympathetic denervation in an angiotensin II-induced hypertensive mouse model, using phenol to disrupt sympathetic nerve function and reduce blood pressure.
07:31
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
0 Views •
Cited by 1 •
2019
Proteomic profiling of tyrosine-nitrated proteins has been a challenging technique due to the low abundance of the 3-nitrotyrosine modification. Here we describe a novel approach for nitropeptide enrichment and profiling by using Angiotensin II as the model. This method can be extended for other in vitro or in vivo systems.
09:51
Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy
0 Views •
Cited by 2 •
2017
Here we present a protocol to image cells expressing green fluorescent protein-tagged angiotensin type 1a receptors during endocytosis initiated by angiotensin II treatment. This technique includes labeling lysosomes with a second fluorescent marker, and then utilizing software to analyze the co-localization of receptor and lysosome in three dimensions over time.
FAQs
AT1-receptor activation links Angiotensin II signaling to several coordinated cardiovascular and renal effects. It narrows blood vessels, which increases vascular tone and supports a rise in blood pressure. It also promotes aldosterone release, followed by greater sodium and water retention. Together, these responses influence both immediate vascular resistance and longer-term control of circulating fluid balance.
Aldosterone provides a hormonal link between Angiotensin II signaling and fluid retention. After Angiotensin II stimulates its release, sodium and water retention become part of the response, rather than the effect being limited to vascular narrowing. This connection matters pharmacologically because altering the pathway can influence both blood pressure and the fluid balance that supports it.
Excessive signaling becomes harmful because the same responses that support pressure and fluid regulation can remain overactive. Persistent vascular effects contribute to hypertension, while continued aldosterone-associated sodium and water retention can sustain pressure and fluid loads. In pharmacology, this pathway is therefore linked not only to elevated blood pressure but also to cardiac remodeling and kidney injury.
These drug classes reduce Angiotensin II signaling at different points. Angiotensin-converting enzyme inhibitors act on the enzyme step that generates Angiotensin II from Angiotensin I, whereas angiotensin receptor blockers reduce the response produced through Angiotensin II receptors. Both approaches limit downstream effects such as vasoconstriction, aldosterone release, and sodium and water retention.
Angiotensin II-directed therapy is relevant to conditions in which this signaling contributes to abnormal pressure or organ stress. The overview specifically identifies hypertension, heart failure, and related cardiovascular or renal conditions as clinical settings for angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Their shared rationale is to reduce effects involving vascular tone, fluid retention, and tissue injury.
In pharmacology, Angiotensin II connects receptor signaling with clinically important cardiovascular and renal outcomes. Its effects on vascular tone and fluid balance help explain hypertension, while excessive signaling is associated with cardiac remodeling and kidney injury. Studying these links provides the rationale for evaluating drugs that reduce angiotensin-converting enzyme activity or block angiotensin receptor effects.